Preparation method of blood perfusion device filler for decomposing phenylalanine in blood
By grafting phenylalanine ammonia lyase on the surface of polystyrene resin particles, the efficient decomposition of phenylalanine in the blood is achieved, the problem of non-specific adsorption and beneficial body fluid loss in the prior art is solved, and the blood is expanded The indication range of perfusion devices and improve efficiency.
Patent Information
- Application Number
- CN202211092398.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-08
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-09-08
AI Technical Summary
The adsorbent material of existing blood perfusion device fillers is limited, resulting in non-specific adsorption, resulting in the loss of beneficial body fluid components in the human body, limiting the scope of clinical indications of perfusion device.
PolyN,N-diethylacrylamide-acrylic acid modified polystyrene resin particles are grafted on the surface, and phenylalanine ammonia lyase is achieved through catalytic reaction with phenylalanine in the blood to achieve its efficient decomposition.
The indication range of blood perfusion device has been expanded, the specific adsorption capacity has been improved, the stability and efficiency of blood components have been ensured, and the blood perfusion time has been shortened.
Smart Images

Figure CN115591036B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of hemoperfusion devices, and in particular relates to a method for preparing a hemoperfusion device filler capable of decomposing phenylalanine in blood. Background Art
[0002] At present, hemoperfusion is a blood purification technology that introduces blood into a perfusion device filled with solid adsorbents to remove exogenous or endogenous toxins, drugs or metabolic wastes in the blood that cannot be removed by dialysis through adsorption. It is mainly used to rescue drug and poison poisoning, and can also be used in combination with hemodialysis to remove macromolecular toxins in patients with chronic renal failure who are undergoing maintenance dialysis.
[0003] Since the solid adsorbents filled inside are made of polystyrene resin or activated carbon, most of them currently rely on direct supply from suppliers, and users have little independent research and development. The types of substances that can be adsorbed by the adsorbents are limited, and the molecular weight of the adsorbed substances cannot be accurately controlled, making the blood perfusion device mostly non-specific adsorption. During the clinical use of blood perfusion devices, it often happens that while certain pathogenic substances are effectively adsorbed, other body fluid components with similar molecular weights are also adsorbed. This will lead to the loss of beneficial body fluid components in the human body and cause some potential health risks.
[0004] At present, some users have made different degrees of modification and reprocessing of solid adsorbents, but the filler matrix is still limited to the product properties of the resin itself, which makes it difficult to flexibly choose in actual clinical applications. The existing modification or modification methods have not made fundamental changes to the basic structure of the resin itself, and the problem of non-specific adsorption has not been well solved. Clinicians cannot choose the corresponding filler perfusion device according to specific needs, which limits the clinical indication range of the perfusion device. Summary of the invention
[0005] The present invention provides a method for preparing a blood perfusion device filler for decomposing phenylalanine in blood, thereby solving the above-mentioned problem.
[0006] The technical solution of the present invention is achieved as follows: A method for preparing a blood perfusion device filler for decomposing phenylalanine in blood comprises the following steps:
[0007] Step 1, mixing acryloyl chloride, dichloromethane and diethylamine to obtain solution C;
[0008] Step 2, adding magnesium sulfate and hydroquinone to solution C respectively and treating the solution to obtain substance A;
[0009] Step 3, after fully mixing substance A, tetrahydrofuran, acrylic acid, azobisisobutyronitrile and polystyrene resin particles, filtering, washing and drying them respectively to obtain substance B;
[0010] Step 4: Add substance B to phosphate buffer, add phenylalanine ammonia lyase and mix well, then filter, wash and dry to obtain a finished product.
[0011] As a preferred embodiment, the method of uniformly mixing acryloyl chloride, dichloromethane and diethylamine in step 1 comprises the following steps:
[0012] Step 10, dissolving acryloyl chloride in dichloromethane to obtain solution A;
[0013] Step 11, dissolving diethylamine in dichloromethane to obtain solution B;
[0014] Step 12: Under nitrogen flow, slowly add solution A into solution B using a constant pressure dropping funnel until the addition is complete, thereby obtaining solution C.
[0015] As a preferred embodiment, in step 1, the addition ratio of acryloyl chloride, dichloromethane and diethylamine is acryloyl chloride (ml): dichloromethane (ml): diethylamine (ml) = 1: (8-12): (4-5).
[0016] As a preferred embodiment, the method for post-treatment by adding magnesium sulfate to solution C in step 2 is to dry overnight and then filter, and heat the filtrate in a water bath at 39° C. for 110 min, and then heat the filtrate in a water bath at 55° C. for 45 min;
[0017] The method for post-treatment after adding hydroquinone to solution C in step 2 is to concentrate it at 9.4 mmHg and 82° C. to obtain substance A.
[0018] As a preferred embodiment, before adding magnesium sulfate and hydroquinone to solution C in step 2, solution C is placed in an ice water bath for stirring reaction, filtered, and rinsed with distilled water.
[0019] As a preferred embodiment, in step 2, the ratio of solution C, magnesium sulfate, and hydroquinone is solution C (ml): magnesium sulfate (g): hydroquinone (g) = (400-500): (15-20): 1.
[0020] As a preferred embodiment, in step 3, the addition ratio of substance A, tetrahydrofuran, acrylic acid, azobisisobutyronitrile, and polystyrene resin particles is substance A (g): tetrahydrofuran (ml): acrylic acid (g): azobisisobutyronitrile (mg): polystyrene resin particles (g) = 3: (30-45): 0.5: 8: 9.
[0021] As a preferred embodiment, the method for fully mixing in step 3 is to introduce nitrogen and carry out copolymerization in a constant temperature water bath at 70° C. for 24 hours;
[0022] The washing method in step 3 is to repeatedly wash with 70% ethanol solution;
[0023] The drying method in step 3 is vacuum drying.
[0024] As a preferred embodiment, the addition ratio of substance B, phosphate buffer and phenylalanine ammonia lyase in step 4 is substance B (g): phosphate buffer (ml): phenylalanine ammonia lyase (mg) = 9: (20-25): 5
[0025] As a preferred embodiment, the method for uniform mixing in step 4 is to oscillate at a speed of 120 rpm for 12 hours at a constant temperature of 4°C;
[0026] The washing method in step 4 is to use phosphate buffer for washing;
[0027] The drying method in step 4 is vacuum drying.
[0028] After adopting the above technical solution, the beneficial effects of the present invention are:
[0029] 1. The poly-N,N-diethylacrylamide-acrylic acid modified filler resin particles with phenylalanine ammonia lyase (PAL) immobilized on the surface prepared by the present invention can decompose phenylalanine in the blood, thereby expanding the scope of indications of the previous hemoperfusion device;
[0030] 2. Compared with the conventional disposable hemoperfusion device fillers, the fillers of the present invention use polystyrene resin particles modified with poly-N,N-diethylacrylamide-acrylic acid and grafted with phenylalanine ammonia lyase (PAL) on the surface, which can efficiently remove phenylalanine in the blood, has no effect on other substances in the blood, and has stronger specificity;
[0031] 3. The surface covering layer of the modified filler of the hemoperfusion device of the present invention is poly-N,N-diethylacrylamide-acrylic acid, which has good biocompatibility and more stable hemodynamics;
[0032] 4. The reaction between the filler and a single substance in the blood is more efficient, shortening the overall blood perfusion time and improving efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0034] Figure 1 It is a schematic diagram of the process of the present invention. DETAILED DESCRIPTION
[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] Example 1
[0037] like Figure 1 As shown, a method for preparing a blood perfusion device filler for decomposing phenylalanine in blood is as follows: 46.7 ml of acryloyl chloride is dissolved in 30 ml of dichloromethane, and the solution is stirred evenly to obtain solution A.
[0038] Dissolve 208 ml of diethylamine in 450 ml of dichloromethane and stir evenly to obtain solution B.
[0039] Under the condition of nitrogen (N2), the above solution A was slowly added into solution B at a rate of about 1.5S / drop using a constant pressure dropping funnel until the drop was complete, thereby obtaining solution C.
[0040] Solution C was placed in an ice-water bath and stirred magnetically for 4 hours. After the reaction was complete, the solid product diethylamine salt was filtered out, and the filtrate was rinsed with distilled water for 3 times to remove the residual acryloyl chloride.
[0041] Add 25g of magnesium sulfate and dry overnight, then filter out the magnesium sulfate pentahydrate crystals. Heat the filtrate in a water bath to 39°C and maintain the constant temperature for 110 minutes to remove dichloromethane. Then adjust the water bath to 55°C and maintain the constant temperature for 45 minutes to remove diethylamine.
[0042] 1.5 g of hydroquinone was added to the remaining filtrate, and the mixture was concentrated by rotary evaporation at 9.4 mmHg and 82° C. for 90 seconds to obtain N,N-diethylacrylamide.
[0043] Take 15 g of the obtained N,N-diethylacrylamide and add it to 200 ml of tetrahydrofuran, add 2.5 g of acrylic acid and 40 mg of azobisisobutyronitrile, stir well and then add 45 g of polystyrene resin particles, introduce nitrogen (N2), place in a constant temperature water bath at 70°C, and copolymerize for 24 hours.
[0044] After the reaction was completed, the resin particles were filtered out, washed repeatedly three times with a 70% ethanol solution, and then vacuum dried to obtain modified polystyrene resin particles with a poly (N, N-diethylacrylamide-acrylic acid) layer on the surface.
[0045] Take 45g of modified polystyrene resin particles and add them to 120ml phosphate buffer (50mM, pH 7.4), add 25mg phenylalanine ammonia lyase (PAL) at the same time, and mix thoroughly. Oscillate the reaction at a speed of 120rpm at a constant temperature of 4℃ for 12 hours. After the reaction is completed, filter out the product, wash it several times with phosphate buffer (50mM, pH 7.4), and then vacuum dry it to obtain poly N,N-diethylacrylamide-acrylic acid modified filler resin particles with phenylalanine ammonia lyase (PAL) fixed on the surface.
[0046] The obtained product is modified filler resin particles having the function of decomposing phenylalanine (PA), which can be used as filler columns of hemoperfusion apparatus to reduce the effect of phenylalanine (PA) in blood.
[0047] Example 2
[0048] like Figure 1 As shown, a method for preparing a blood perfusion device filler for decomposing phenylalanine in blood is as follows: 70 ml of acryloyl chloride is dissolved in 45 ml of dichloromethane, and the solution is stirred evenly to obtain solution A.
[0049] Dissolve 280 ml of diethylamine in 515 ml of dichloromethane and stir evenly to obtain solution B.
[0050] Under the condition of nitrogen (N2), the above solution A was slowly added into solution B at a rate of about 1.5S / drop using a constant pressure dropping funnel until the drop was complete, thereby obtaining solution C.
[0051] Solution C was placed in an ice-water bath and stirred magnetically for 4 hours. After the reaction was complete, the solid product diethylamine salt was filtered out, and the filtrate was rinsed with distilled water for 3 times to remove the residual acryloyl chloride.
[0052] Add 34g of magnesium sulfate and dry overnight, then filter out the magnesium sulfate pentahydrate crystals. Heat the filtrate in a water bath to 39°C and maintain the constant temperature for 110 minutes to remove dichloromethane. Then adjust the water bath to 55°C and maintain the constant temperature for 45 minutes to remove diethylamine.
[0053] 2.3 g of hydroquinone was added to the remaining filtrate, and the mixture was concentrated by rotary evaporation at 9.4 mmHg and 82° C. for 90 seconds to obtain N,N-diethylacrylamide.
[0054] Take 20 g of the obtained N,N-diethylacrylamide and add it to 200 ml of tetrahydrofuran, add 3.3 g of acrylic acid and 53 mg of azobisisobutyronitrile, stir well and then add 60 g of polystyrene resin particles, introduce nitrogen (N2), place in a constant temperature water bath at 70°C, and copolymerize for 24 hours.
[0055] After the reaction was completed, the resin particles were filtered out, washed repeatedly three times with a 70% ethanol solution, and then vacuum dried to obtain modified polystyrene resin particles with a poly (N, N-diethylacrylamide-acrylic acid) layer on the surface.
[0056] Take 55g of modified polystyrene resin particles and add them to 122ml phosphate buffer (50mM, pH 7.4), add 31mg phenylalanine ammonia lyase (PAL) at the same time, and mix thoroughly. Oscillate the reaction at a speed of 120rpm at a constant temperature of 4℃ for 12 hours. After the reaction is completed, filter out the product, wash it several times with phosphate buffer (50mM, pH 7.4), and then vacuum dry it to obtain poly N,N-diethylacrylamide-acrylic acid modified filler resin particles with phenylalanine ammonia lyase (PAL) fixed on the surface.
[0057] The obtained product is modified filler resin particles having the function of decomposing phenylalanine (PA), which can be used as filler columns of hemoperfusion apparatus to reduce the effect of phenylalanine (PA) in blood.
[0058] Example 3
[0059] like Figure 1 As shown, a method for preparing a blood perfusion device filler for decomposing phenylalanine in blood is as follows: 100 ml of acryloyl chloride is dissolved in 64 ml of dichloromethane, and the solution is stirred evenly to obtain solution A.
[0060] Dissolve 500 ml of diethylamine in 1136 ml of dichloromethane and stir evenly to obtain solution B.
[0061] Under the condition of nitrogen (N2), the above solution A was slowly added into solution B at a rate of about 1.5S / drop using a constant pressure dropping funnel until the drop was complete, thereby obtaining solution C.
[0062] Solution C was placed in an ice-water bath and stirred magnetically for 4 hours. After the reaction was complete, the solid product diethylamine salt was filtered out, and the filtrate was rinsed with distilled water for 3 times to remove the residual acryloyl chloride.
[0063] After adding 72g of magnesium sulfate and drying overnight, the magnesium sulfate pentahydrate crystals were filtered off. The filtrate was placed in a water bath and heated to 39°C, and the temperature was maintained for 110 minutes to remove dichloromethane. The water bath was then adjusted to heat to 55°C, and the temperature was maintained for 45 minutes to remove diethylamine.
[0064] 3.6 g of hydroquinone was added to the remaining filtrate, and the mixture was concentrated by rotary evaporation at 9.4 mmHg and 82° C. for 90 seconds to obtain N,N-diethylacrylamide.
[0065] Take 30 g of the obtained N,N-diethylacrylamide and add it to 450 ml of tetrahydrofuran, add 5 g of acrylic acid and 80 mg of azobisisobutyronitrile, stir well and then add 90 g of polystyrene resin particles, introduce nitrogen (N2), place in a constant temperature water bath at 70°C, and copolymerize for 24 hours.
[0066] After the reaction was completed, the resin particles were filtered out, washed repeatedly three times with a 70% ethanol solution, and then vacuum dried to obtain modified polystyrene resin particles with a poly (N, N-diethylacrylamide-acrylic acid) layer on the surface.
[0067] Take 60g of modified polystyrene resin particles and add them to 167ml phosphate buffer (50mM, pH 7.4), add 33mg phenylalanine ammonia lyase (PAL) at the same time, and mix thoroughly. Oscillate the reaction at a speed of 120rpm at a constant temperature of 4℃ for 12 hours. After the reaction is completed, filter out the product, wash it several times with phosphate buffer (50mM, pH 7.4), and then vacuum dry it to obtain poly N,N-diethylacrylamide-acrylic acid modified filler resin particles with phenylalanine ammonia lyase (PAL) fixed on the surface.
[0068] The obtained product is modified filler resin particles having the function of decomposing phenylalanine (PA), which can be used as filler columns of hemoperfusion apparatus to reduce the effect of phenylalanine (PA) in blood.
[0069] Comparative Example
[0070] The blood perfusion device used in the present invention comprises a column, the top threaded cover of the column is provided with an upper cover body, the top of the upper cover body is provided with a liquid inlet, the bottom threaded cover of the column is provided with a lower cover body, the bottom of the lower cover body is provided with a liquid outlet, the column is filled with modified polystyrene resin particles prepared by the present invention and unmodified resin particles, respectively, plasma is injected into the blood perfusion device containing modified polystyrene resin particles and unmodified resin particles through a peristaltic pump, and the output plasma is detected by fluorescence method, and the detection results of the modified resin particles (obtained in Example 1) are shown in the following table:
[0071]
[0072] The test results of unmodified resin particles are shown in the following table:
[0073]
[0074] It can be seen from the above table that plasma has a good effect of removing phenylalanine by passing through the modified polystyrene resin particles prepared by the present invention.
[0075] Phenylketonuria (PKU) is a common amino acid metabolic disease. It is caused by the deficiency of phenylalanine hydroxylase (PAH), which is necessary in the phenylalanine (PA) metabolic pathway, so that phenylalanine cannot be converted into tyrosine, resulting in the accumulation of phenylalanine and its keto acid, and a large amount of discharge from urine. This disease is relatively common in inherited amino acid metabolic deficiency diseases. The main clinical features are abnormal electroencephalogram, mental retardation, mental neurological symptoms, eczema, skin scratch signs, pigment loss and mouse urine odor, etc. Low phenylalanine diet therapy is the only method for treating classic PKU at present. The present invention prepares N, N-diethylacrylamide, copolymerizes N, N-diethylacrylamide on the surface of polystyrene resin particles and fixes it on the surface of resin particles, grafts acrylic acid groups, and uses carboxyl groups to undergo amidation reaction with free phenylalanine ammonia lyase (PAL) to immobilize, thereby forming modified polystyrene resin particles with the function of decomposing phenylalanine. When phenylalanine (PA) in the blood flows through a blood perfusion device made of the resin particles as fillers, it undergoes a catalytic reaction with phenylalanine ammonia lyase (PAL) fixed on the surface of the resin particles and is decomposed, thereby reducing the phenylalanine content in the blood.
[0076] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a blood perfusion device filler for decomposing phenylalanine in blood, characterized in that: The steps include: Step 1, mixing acryloyl chloride, dichloromethane and diethylamine to obtain solution C; Step 2, adding magnesium sulfate and hydroquinone to solution C respectively and treating the solution to obtain substance A; Step 3, after fully mixing substance A, tetrahydrofuran, acrylic acid, azobisisobutyronitrile and polystyrene resin particles, filtering, washing and drying them respectively to obtain substance B; Step 4, adding substance B to phosphate buffer, adding phenylalanine ammonia lyase and mixing well, filtering, washing and drying respectively to obtain a finished product; The method for uniformly mixing acryloyl chloride, dichloromethane and diethylamine in step 1 comprises the following steps: Step 10, dissolving acryloyl chloride in dichloromethane to obtain solution A; Step 11, dissolving diethylamine in dichloromethane to obtain solution B; Step 12, under nitrogen flow, slowly add solution A to solution B using a constant pressure dropping funnel until the dropping is complete, thereby obtaining solution C; In the step 1, the addition ratio of acryloyl chloride, dichloromethane and diethylamine is acryloyl chloride (ml): dichloromethane (ml): diethylamine (ml) = 1: (8-12): (4-5); The method for post-treatment of adding magnesium sulfate to solution C in step 2 is to filter after drying overnight, and heat the filtrate in a water bath at 39° C. for 110 min, and then heat the filtrate in a water bath at 55° C. for 45 min; the method for post-treatment of adding hydroquinone to solution C in step 2 is to concentrate at 9.4 mmHg and 82° C. to obtain substance A; The method for fully mixing in step 3 is to introduce nitrogen and perform copolymerization in a constant temperature water bath at 70° C. for 24 hours; the method for washing in step 3 is to repeatedly wash with 70% ethanol solution; the method for drying in step 3 is vacuum drying; In the step 4, the addition ratio of substance B, phosphate buffer and phenylalanine ammonia lyase is substance B (g): phosphate buffer (ml): phenylalanine ammonia lyase (mg) = 9: (20-25): 5; The method of mixing uniformly in step 4 is to shake at a speed of 120 rpm for 12 hours at a constant temperature of 4° C.; the method of washing in step 4 is to wash with phosphate buffer; The drying method in step 4 is vacuum drying.
2. The method for preparing a hemoperfusion device filler for decomposing phenylalanine in blood according to claim 1, characterized in that: Before adding magnesium sulfate and hydroquinone to solution C in step 2, solution C is placed in an ice water bath for stirring reaction, filtered, and rinsed with distilled water.
3. The method for preparing a hemoperfusion device filler for decomposing phenylalanine in blood according to claim 1, characterized in that: In step 2, the ratio of solution C, magnesium sulfate, and hydroquinone is solution C (ml): magnesium sulfate (g): hydroquinone (g) = (400 500): (15 20):
1.
4. The method for preparing a hemoperfusion device filler for decomposing phenylalanine in blood according to claim 1, characterized in that: In the step 3, the addition ratio of substance A, tetrahydrofuran, acrylic acid, azobisisobutyronitrile, and polystyrene resin particles is substance A (g): tetrahydrofuran (ml): acrylic acid (g): azobisisobutyronitrile (mg): polystyrene resin particles (g) = 3: (30-45): 0.5: 8: 9.
Citation Information
Patent Citations
Blood-purifying adsorbing agent for cleaning antibody
CN101279242A
Novel Microbial Succinic Acid Producers And Purification Of Succinic Acid
CN104877935A
Composition for regulating activity of fatty acid synthase and application thereof
CN111743919A
Immobilized catalytically active substance and method of preparing the same
US4138292A
Extracorporeal capturing of specific BIO-macromolecular entities from extracellular body fluids
WO2002053251A1
